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Background Results from apparently conclusive meta-analyses may be false. A limited number of events from a few small trials and the associated random error may be under-recognized sources of spurious findings. The information size (IS, i.e. number of participants) required for a reliable and conclusive meta-analysis should be no less rigorous than the sample size of a single, optimally powered randomized clinical trial. If a meta-analysis is conducted before a sufficient IS is reached, it should be evaluated in a manner that accounts for the increased risk that the result might represent a chance finding (i.e. applying trial sequential monitoring boundaries).
Methods
We analysed 33 meta-analyses with a sufficient IS to detect a treatment effect of 15% relative risk reduction (RRR). We successively monitored the results of the meta-analyses by generating interim cumulative meta-analyses after each included trial and evaluated their results using a conventional statistical criterion (a ¼ 0.05) and two-sided Lan-DeMets monitoring boundaries. We examined the proportion of false positive results and important inaccuracies in estimates of treatment effects that resulted from the two approaches.
Results
Using the random-effects model and final data, 12 of the metaanalyses yielded P4a ¼ 0.05, and 21 yielded P 4 a ¼ 0.05. False positive interim results were observed in 3 out of 12 meta-analyses with P4a ¼ 0.05. The monitoring boundaries eliminated all false positives. Important inaccuracies in estimates were observed in 6 out of 21 meta-analyses using the conventional P 4 a ¼ 0.05 and 0 out of 21 using the monitoring boundaries.
Introduction
There is a risk that meta-analyses report false positive results (i.e. report a treatment effect when in reality there is no effect) or report important inaccuracies in treatment effects. Most discussions regarding false positive results and inaccurate estimation of the treatment effect in meta-analyses have focused on issues such as publication bias, bias due to low methodological quality and heterogeneity in various features of the design and conduct of the included trials. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The possibility that some apparently conclusive meta-analyses may offer spurious estimates of treatment effects because of a limited number of events from a few small trials has received less emphasis. [15] [16] [17] The standards for a meta-analysis should be no less rigorous than standards for a single randomized clinical trial. Thus, the information size (IS) required for a reliable and conclusive meta-analysis should be at least as large as that of a single, optimally powered randomized clinical trial. [17] [18] [19] Theoretical considerations suggest that cumulative meta-analyses of sparse data have a substantial probability of resulting in chance findings, typically overestimating the effects. If the trials in a meta-analysis are homogeneous, the statistical problem translates to what is well-known from single clinical trials: formally significant results in small trials and in early terminated larger trials tend to overestimate effect sizes and have a high risk of false positives. 20, 21 If the trials in a meta-analysis are assumed to be heterogeneous, the diversity of effects across underlying sub-populations also needs to be taken into account in assessing the reliability of the accumulated amount of data. 19 Several authors have warned against relying upon the conventional statistical criterion (two-sided a ¼ 0.05) for deciding whether a treatment effect exists. [13] [14] [15] [16] This is especially critical when evaluating meta-analyses that have not achieved a required IS. [17] [18] [19] To avoid false conclusions, Pogue and Yusuf recommended constructing Lan-DeMets sequential monitoring boundaries for a meta-analysis, 17 analogous to interim monitoring in a single randomized clinical trial. They used an O'Brien-Fleming a-spending function to control the desired maximum risk of type I error. 22, 23 This approach is more conservative when a meta-analysis includes only a limited number of events from a few small trials, but comes close to the conventional criterion when the total number of patients in a meta-analysis reaches the required IS. It may present a valuable tool for monitoring and quantifying the reliability of metaanalytic inference before sufficient evidence has been accumulated. 18, 19 IS determination for monitoring boundaries in meta-analysis resembles, to some extent, its counterpart for a single randomized clinical trial: it depends on an a priori assumed treatment effect, control group event rate and desired maximum risk of statistical error (conventionally set to a ¼ 0.05 and ¼ 0.2). However, it also differs since it also depends on the amount of heterogeneity among trials in the metaanalysis. 19, 22, 23 Pogue and Yusuf did not take into account heterogeneity across trials when they determined the IS of a meta-analysis. 17 From a metaanalysis IS perspective this is equivalent to ignoring the risk of early over-representation of subpopulations. Therefore, we have recommended obtaining a heterogeneity corrected IS (HIS), hereby introducing the concept of trial sequential monitoring boundaries (TSMB), i.e. discrete sequential monitoring boundaries applied to trials in a cumulative metaanalysis. 19, 22, 23 At present, there is no empirical evidence regarding the frequency of false positive results and overestimation of treatment effects based on these various approaches. To inform these issues we selected published meta-analyses that surpassed their HIS, and generated cumulative interim meta-analyses as trials accumulated. We accepted the final results (i.e. the P-value and the pooled estimate of effect) of each published meta-analysis as representing the best estimate of the 'truth'. We compared interim results with the final results to determine the proportion of meta-analyses where false positive results and inaccurate estimates of effect sizes occurred, either due to crossing of a conventional P-value threshold or due to crossing of the TSMB.
Methods
Inclusion criteria of meta-analyses We screened 62 meta-analyses, previously assembled for two empirical research studies on binary outcomes conducted at the Copenhagen Trial Unit. 3, 7 The metaanalyses of the first study were selected from all identifiable meta-analyses in 1997, including at least one randomized trial with more than 1000 participants. 3 The meta-analyses of the second study represented a random sample of meta-analyses from The Cochrane Library, Issue 2, 2001 that assessed a binary outcome and pooled at least five trials of which at least one reported adequate and one reported inadequate allocation concealment. 7 The two empirical studies explored whether reported methodological factors affect the estimated treatment effects in randomized clinical trials. 3, 7 In both studies, two authors independently assessed the reported quality of the included trials based on generation of allocation sequence, allocation concealment and blinding. 3, 7 Disagreements were resolved by discussion or consulting an adjudicator.
From these 62 meta-analyses, we selected the ones that met the following eligibility criteria: the total number of participants in a meta-analysis exceeded its HIS based on the IS assumptions chosen for our primary analysis (see last paragraph in 'Methods' section)-this assured that a sufficient amount of evidence was eventually available; and the metaanalysis included at least two trials with adequate generation of allocation sequence, adequate allocation concealment and adequate blinding and at least 100 outcome events-this assured that a considerable amount of data came from trials with low risk of bias ('systematic error'). [1] [2] [3] [4] In all meta-analyses, we calculated the effect of the experimental intervention in a way that a relative risk <1.0 (fewer events in experimental group) indicated superiority of the experimental intervention over the control intervention. Thus, when the meta-analyses originally measured the number of favourable outcomes (e.g. clinical cure), we considered the complementary unfavourable outcome (e.g. lack of clinical cure) instead.
Required meta-analysis IS
The sample size, n, required for a single randomized clinical trial, can be calculated using the formula
Here ¼ C À E denotes the intervention effect ( C and E being the incidence in the control group and in the intervention group, respectively) and
e. equal size of the intervention and the control group. We set the statistical error levels to a ¼ 0.05 and ¼ 0.2 (1À ¼ 80% power) for both the random-and fixedeffects model analyses. We estimated C by metaanalysing the control group event proportions of the low-bias risk trials, i.e. the trials meeting the second of the above two eligibility criteria. We obtained the intervention group event rate, E from the metaanalysed control group event rate and an a priori estimate of a realistic and relevant treatment effect. In the random-effects model analyses, we calculated the HIS by using the formula HIS ¼ n/(1ÀI 2 ) to account for the extra model variation. 19 Here, I 2 is the measure of the impact of heterogeneity in a metaanalysis proposed by Higgins and Thompson. 25 For each meta-analysis, we used the I 2 estimate of the final meta-analysis to estimate HIS. In the fixed-effect model analyses, we did not heterogeneity correct the IS as this would potentially be seen as in violation with the underlying model assumptions.
Statistical analysis
We assessed the meta-analyses with trial sequential analysis using TSMB. 19 We generated interim looks after the termination of each trial. The sequence of trials was determined by year of publication. If two or more trials were published the same year, they were ordered alphabetically according to the last name of the first author. The TSMB is based on the LanDeMets a-spending function that controls the overall type I error by spending this in an appropriate manner, as statistical tests are employed throughout the accumulation of trials. 22 For our study, we chose the a-spending function that results in the wellknown O'Brien-Fleming monitoring boundaries. 23 This a-spending is particularly suitable for metaanalysis since it spends the type I error exponentially to the increment of accumulated patients, and thus, ensures that TSMB is largely insensitive to the number of interim looks performed before reaching the required IS. The a-spending is a function of the number of included participants divided by the required IS. We refer to this fraction as the information fraction. We accepted the final treatment effect point estimate and the corresponding P-value of each published meta-analysis as representing the best estimate of the 'truth'. Here the P-value was obtained from the conventional two-sided Mantel-Haenszel Z-test statistic, which is assumed to follow a standard normal distribution. Thus, obtaining a P-value 40.05 corresponds to the absolute value of the MantelHaenszel Z-test statistic being 51.96. To streamline the used terminology in the rest of this paper, we will use the crossing of |Z| ¼ 1.96 to describe the event where an interim meta-analysis went from 'P40.05' to 'P 4 0.05'. We investigated the frequency of false positive results in the meta-analyses. A false positive result was defined as the situation where one or more generated cumulative interim meta-analysis looks showed crossing of |Z| ¼ 1.96, but would eventually return to |Z| < 1.96 in the final meta-analysis. We obtained the proportion of false positives for our primary analysis and sensitivity analyses. The number of meta-analyses containing false positive results serves as the numerator and all meta-analyses with final P4a ¼ 0.05 serve as the denominator.
From all published meta-analyses with P < a ¼ 0.05, we identified the relative risk reductions (RRRs) from the first generated interim looks where |Z| 5 1.96.
Separately, we identified the RRRs from the first generated interim look where the TSMB were crossed. We measured the absolute difference between these RRRs and the RRR from the corresponding final metaanalysis. That is, letting RRR F denote the RRR the final meta-analysis, and RRR i the RRR estimated at an interim look, the absolute difference was measured as abs(RRR F -RRR i ). When the point estimate of the final meta-analysis, RRR F , was <25%, we considered an a priori absolute difference 410% to be an important inaccuracy in the estimated treatment effect. When the point estimate of the RRR from a final meta-analysis was 425%, we considered an a priori absolute difference 420% to be an important inaccuracy in the estimated treatment effect. We obtained the proportions of important inaccuracies in point estimates (as defined above) for our primary analysis and sensitivity analyses. Meta-analyses in which important inaccuracies in estimates were observed after first crossings served as numerators. All meta-analyses with final P 4 0.05 that crossed |Z| ¼ 1.96 before or simultaneous of surpassing their respective HIS served as denominators. We recorded the number of trials and information fractions at which the first interim crossings were observed. Furthermore, we recorded which of the meta-analyses that did not cross |Z| ¼ 1.96 before or simultaneous of surpassing their respective HIS. We performed the latter because our study focuses on the reliability of early results yielding P 4 a ¼ 0.05 before reaching a required IS.
All statistical analyses were performed using both the random-effects model and the fixed-effect model. Random effects are the primary analysis and fixed effect represents a sensitivity analysis. All analyses were based on standard IS calculations assuming a priori relevant and realistic estimates of treatment effects RRR ¼ 15% and RRR ¼ 25%. The RRR ¼ 15% are the primary analysis and the RRR ¼ 25% represents a sensitivity analysis.
Results Figure 1 presents the selection of meta-analyses for the primary analysis and sensitivity analyses. Table 1 presents characteristics of the 33 metaanalyses from 28 reviews that were included. The median number of trials was 9 (range: 4-77), the median number of participants was 4133 participants (range: 626-44102), median I 2 was 27% (range: 0-89%) and median HIS was 2119 participants (range: 507-29902).
False positive results
Using the random-effects model, the results of 12 of the 33 final meta-analyses yielded P4a ¼ 0.05. [26] [27] [28] [46] [47] [48] [49] [50] [51] [52] We observed false positive results in 3 of these 12 meta-analyses. [26] [27] [28] The TSMB eliminated all such false positive results when a RRR ¼ 15% was assumed. When assuming RRR ¼ 25% for the calculation of HIS, the TSMB failed to eliminate one of the three false positive results. 26 In the fixed-effect model, nine final meta-analyses yielded P4a ¼ 0.05. We observed false positive results in three of these nine meta-analyses. 27, 28, 46 All of these meta-analyses contained false positive results in favour of the control intervention.
The TSMB eliminated two false positive results when a RRR ¼ 15% was assumed. 28, 46 When assuming RRR ¼ 25% for the calculation of IS, the TSMB eliminated one of the three false positive results. 27 The three meta-analysis had estimated heterogeneity, I 2 , of 24, 21 and 30%, respectively, which was not corrected for due the homogeneity assumption inherent of the fixed-effect model.
Important inaccuracies in estimated treatment effects
Using the random-effects model, the results of 21 of 33 final meta-analyses yielded P 4 a ¼ 0.05. 27, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] The obtained RRR estimates from the final metaanalyses were <25% in 10 meta-analyses and 425% in 11 meta-analyses. Eighteen of the 21 meta-analyses crossed |Z| ¼ 1.96 before or concomitantly to surpassing the HIS based on the assumption of RRR ¼ 15%. Among these, the first interim crossing of |Z| ¼ 1.96 resulted in important inaccuracies in point estimates in six meta-analyses. [29] [30] [31] [32] [33] [34] Crossing times and the corresponding RRR estimates for these six meta-analyses are presented in Table 3 . All important inaccuracies in point estimates were observed after one or two trials, and before 30% of the information fraction was reached. One of the six meta-analyses, in which early inaccurate estimates were observed, yielded a final RRR estimate <25% 33 ; the remaining five yielded final RRR estimates 425%. One of the six inaccurate estimates was an underestimation of the final treatment effect 34 the remaining five were overestimations. The crossing of TSMB did not result in any inaccurate estimates when assuming RRR ¼ 15%. Crossing times and the corresponding RRR estimates of the 15 final meta-analyses without important inaccuracies in early point estimates are presented in Table 4 .
When assuming RRR ¼ 25%, 16 meta-analyses crossed |Z| ¼ 1.96 before or concomitantly to surpassing the HIS. Among these, the first interim crossing of |Z| ¼ 1.96 resulted in important inaccuracies in point estimates in five meta-analyses, [29] [30] [31] 33, 34 and the first interim crossing of TSMB resulted in one important inaccuracy.
Using the fixed-effect model the results of 24 of the 33 final meta-analysis yielded P 4 a ¼ 0.05. 26, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] The obtained RRR estimates from the final meta-analyses were <25% in 14 meta-analyses and 425% in 10 meta-analyses. Twenty-three meta-analyses crossed |Z| ¼ 1.96 before or concomitantly to surpassing the required IS based on the assumption of RRR ¼ 15%. Among these, the first interim crossing of |Z| ¼ 1.96 resulted in important inaccuracies in point estimates in eight meta-analyses. 26, [29] [30] [31] [32] [33] [34] 46 One of the eight inaccurate estimates was an underestimation of the final treatment effect, 34 the remaining seven were overestimations. The first interim crossing of TSMB resulted in three important inaccuracies. 26, 29, 32 When assuming RRR ¼ 25%, 19 fixed-effect meta-analyses crossed |Z| ¼ 1.96 before or simultaneously to surpassing the IS. Among these, important inaccuracies were observed in the same meta-analysis as with the assumption of RRR ¼ 15%.
Discussion
Our study suggests that applying trial sequential analyses with IS estimation and TSMB may reduce both the number of false positive results and the number of important inaccuracies in estimates of treatment effects. These advantages may come with a trade-off of some delay in reaching the point at which statistically significant evidence is considered conclusive.
Early point estimates with statistical support from the conventional P-value criterion were important inaccuracies in 30-40% of the meta-analyses according to the defined threshold. Given that point estimates from meta-analyses will be used as a basis for recommendations in clinical practice guidelines and decision making in individual patient care, grossly erroneous treatment effects can be highly problematic. Spurious results were predominantly 12 meta-analyses yielding P > α = 5% Figure 1 Illustrates the selection process for meta-analyses in the primary analyses and sensitivity analyses 
INFORMATION SIZE AND MONITORING BOUNDARIES IN META-ANALYSES
apparent when <30% of the required IS was reached. However, we cannot preclude that spurious results will appear closer to the required IS. The TSMB markedly reduced the risk of inaccurate point estimates. Assumption of RRR ¼ 15% was required to ensure that TSMB effectively eliminated the problems of early spurious results. Meta-analyses evaluated with monitoring boundaries may not have the same immediate consequences as interim analyses of a single trial. In trials terminated early for benefit or harm, interim analyses show (highly) significant differences that may ethically preclude continuation of a trial. In a metaanalysis context, IS considerations and the applications of monitoring boundaries serve to assess the reliability of retrospectively accumulated evidence. Accordingly, TSMB may serve as a guide for whether more trials should be conducted or not. 53 Often, authors of meta-analyses focus primarily on the point estimates and confidence intervals of the summary effects rather than on whether the summary effects differ significantly from the null. The underlying a-spending function (O'Brien-Fleming in our study) can also be employed to control the width of confidence intervals. 54 We suggest applying the chosen a-spending function for both confidence intervals and statistical tests in meta-analytical practice.
Traditionally, meta-analyses have been conducted retrospectively, combining data from past studies. It can be argued that IS and power calculations may not be meaningful in such retrospective analyses. 55 However, the current setting is changing dramatically. Now, systematic reviews and meta-analyses are recommended before each new randomized trial is conducted and with updated meta-analysis after the closure of the new trial. 53, 56 Furthermore, meta-analyses are increasingly prospectively planned, e.g. as part of development of new medicines or as part of Cochrane systematic reviews going to be updated when new evidence appears or at least every second year. 12 In some 57 In effect, the prospective cumulative meta-analysis serves as a decision tool for planning of future trials that may be included in the meta-analysis. It is in this setting, trial sequential analyses can address the random errors that may arise from repetitive analyses of accumulating data in cumulative meta-analyses. Of course, the trial sequential analysis does not deal with errors introduced due to the inclusion of flawed trials or trials with systematic bias. [1] [2] [3] [4] Due to their more conservative nature, statistically significant results from using TSMB are inevitably obtained later than when using the conventional criterion. The benefits gained from using TSMB weighted against a potential delay in definitively establishing a true treatment effect must be interpreted in the context of the more focused picture of the specific intervention. Thus, the appropriate trade-off between a delay in widespread implementation of an effective treatment and the risk of substantially overestimating a treatment effect, or implementing a treatment without benefit, will depend on the circumstances. When a treatment is the only therapy for a serious condition and has minimal adverse effects and cost, early implementation may be appropriate. When effective treatment is already available, the condition is less serious or adverse outcomes less frequent and the new intervention is associated with appreciable toxicity and cost, waiting for robust results is advisable.
Only 33 meta-analyses from our original data set of 62 meta-analyses were eligible. The relatively small number of meta-analyses precludes definitive conclusions, but leaves us with an idea of the pitfalls the conventional significance criterion in meta-analysis possesses and the advantages we may gain from utilizing TSMB in cumulative meta-analysis instead, in order to draw statistical inference. Our criteria for eligible meta-analyses included a sufficient IS, a minimum number of low-bias risk trials and a minimum total number of events in the low-bias risk trials. One could argue that, among our criteria for high methodological quality, we should have included additional criteria; particularly, loss to follow-up and refraining from trials with early termination. We chose our criteria to maximize the probability that the results obtained from the published meta-analyses would be reliable enough to be considered definitive. 58 The primary and sensitivity choice of RRR for calculation of HIS was small (15%) or moderate (25%). These relatively modest effects are realistic. Most trials evaluate therapies for chronic diseases in which the pathophysiology is multifactorial, and hence, any intervention targeting a single risk factor is unlikely to have more than a moderate treatment effect.
Early false positive results and important inaccuracies in estimates of treatment effects may be spuriously in favour of either the experimental or the control intervention. Both situations can be clinically misleading. For example, the conventional approach would suggest that intense advice is significantly better than standard advice for smoking cessation, while hospital contact and follow-up are worse than standard advice for smoking cessation. 27 Apparently, both of these early claims of superiority and inferiority, respectively, are likely to be spurious. All these approaches are not different in changing the rates of smoking cessation, and this means that additional approaches need to be sought to improve smoking cessation rates.
In another example that we encountered, early results falsely suggested that progestagens might worsen the outcome of patients with endometrial cancer, while there was eventually no intervention effect. 28 Thus, progestagens may be used for other indications in these patients, while a statistically documented harm would lead to a position that these hormones should not be used in the setting of endometrial cancer.
Spurious results can be misleading for clinical practice regardless of the direction of the effect. Focusing on harm, the TSMB used should be adapted to the context. In case an intervention is in widespread use, equally conservative TSMBs should be considered in assessing harm. 59 However, less conservative boundaries may be used for assessing harm when the intervention has not yet been disseminated. 59 Since great uncertainty exists about the magnitude of heterogeneity when a meta-analysis includes only a few trials with a few events, we propose that an a priori estimate of the heterogeneity should be decided upon for the IS calculation. 19, 60 Underestimating the magnitude of heterogeneity will yield an unrealistically small IS and consequently fail to reduce the risk of spurious P-values and pooled treatment effect estimates upon reaching the HIS. Thus, we suggest that a priori estimates of heterogeneity in this setting chiefly should be conservative and reflect either a moderate or large magnitude of heterogeneity. By the same token, heterogeneity is often undetectable or underestimated when only a few trials are included in the meta-analysis. In this setting, the fixed-effect and random-effects models yield similar inferences. Thus, by employing HIS instead of IS in the fixed-effect analysis a number of spurious results could potentially have been evaded. 61 Overall, evaluating statistical significance with TSMB may help in a more appropriate interpretation of meta-analysis results. While our findings require confirmation in larger samples, theoretical considerations also support the use of more stringent standards to avoid false positive results and overestimates of treatment effects from metaanalyses.
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KEY MESSAGES
Meta-analyses with only a limited number of events from a few small trials are prone to report unreliable statistical inferences.
Meta-analytical inferences should not be based solely on the conventional statistical criterion of two-sided a ¼ 0.05.
Meta-analysis IS considerations and trial sequential monitoring boundaries may provide a valuable tool for guarding against false positive results and premature dissemination of marginal or useless interventions.
